Key Market Segments
By Type
-
Capping Agents
-
CleanCap Reagents
-
ARCA (Anti-Reverse Cap Analog)
-
Others
-
-
Nucleotides
-
Modified Nucleic Acids
-
N1-methylpseudouridine-triphosphate
-
5-Methylcytidine triphosphate (5mCTP)
-
Others
-
-
Natural Nucleic Acids
-
Adenine
-
Guanine
-
Cytosine
-
Uracil
-
-
-
Plasmid DNA
-
Enzymes
-
Polymerase
-
RNase Inhibitor
-
DNase
-
Others
-
-
Others
By Application
-
Vaccine Production
-
Therapeutics Production
-
Others
By End Use
-
Biopharmaceutical & Pharmaceutical Companies
-
CROs & CMOs
-
Academic & Research Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Turkey
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Future trends include the increased adoption of personalized mRNA therapies, a rise in self-amplifying and circular RNA research, and the development of next-gen capping technologies to improve mRNA stability and translation.
North America, led by the U.S., dominates the market due to strong biotechnology infrastructure, government support, and major players headquartered in the region.
Key players include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), TriLink BioTechnologies, New England Biolabs, Cytiva (Danaher), BioNTech, Moderna, GenScript, CureVac, and ST Pharm.
Growth is driven by the expanding application of mRNA technology in infectious disease vaccines, cancer therapeutics, and rare genetic disorders, along with heavy R&D investments, government funding, and the need for GMP-compliant raw materials such as nucleotides, capping agents, and enzymes.
The global mRNA synthesis raw materials market was valued at USD 1.70 billion in 2024 and is projected to reach USD 2.67 billion by 2032, growing at a CAGR of 5.81% from 2025 to 2032.